

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in this application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended). A plasmid expression vector polynucleotide which induces anti-HSV antibodies or protective immune responses upon introduction into vertebrate tissue, wherein said vector polynucleotide comprises at least one gene encoding at least one HSV protein or truncated protein, said gene or genes being operably linked to a transcription promoter.

Claim 2. (Currently Amended). The plasmid expression vector polynucleotide of Claim 1, wherein said gene encodes an HSV protein selected from a group consisting of gB, gC, gD, gH, gL, ICP27 and truncated gB.

Claim 3. (Currently Amended). The plasmid expression vector polynucleotide of Claim 1 wherein said gene encodes a carboxy-terminal truncated gB protein.

Claim 4. (Currently Amended). The plasmid expression vector polynucleotide of Claim 3 wherein said truncated gB deletion comprises the amino terminal 707 amino acids of wild type gB.

Claim 5. (Currently Amended). The plasmid expression vector polynucleotide of Claim 4 which is V1Jns:ΔgB.

Claim 6. (Currently Amended). The plasmid expression vector polynucleotide of Claim 2 wherein said gene encodes the HSV protein, gD.

Claim 7. (Currently Amended). The plasmid expression vector polynucleotide of Claim 6 which is V1Jns:gD.

Claim 8. (Currently Amended). A vaccine for inducing an immune response against HSV which comprises a first plasmid expression vector polynucleotide which expresses the HSV

protein gD and a second plasmid expression vector polynucleotide which expresses a carboxy-terminal truncated gB protein.

Claim 9. (Currently Amended). A vaccine of claim 8 wherein said first plasmid expression vector polynucleotide is V1Jns:gD.

Claim 10. (Currently Amended). A vaccine of claim 8 wherein said second plasmid expression vector polynucleotide is V1Jns:ΔgB.

Claim 11. (Currently Amended). A vaccine of claim 10 wherein said first plasmid expression vector polynucleotide is V1Jns:gD.

Claim 12. (Previously Presented). A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing the vaccine according to Claim 11 into a tissue of a vertebrate.

Claim 13. (Currently Amended). A vaccine for inducing immune responses against HSV which comprises the plasmid expression vector polynucleotide of Claim 11 and a pharmaceutically acceptable carrier.

Claim 14. (New). A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing the plasmid expression vector according to Claim 1 into a tissue of a vertebrate.

Claim 15. (New). A vaccine for inducing immune responses against HSV which comprises the plasmid expression vector of Claim 1 and a pharmaceutically acceptable carrier.

Claim 16. (New). A method for inducing immune responses in a vertebrate against HSV epitopes which comprises introducing the plasmid expression vector according to Claim 2 into a tissue of a vertebrate.

Claim 17. (New). A vaccine for inducing immune responses against HSV which comprises the plasmid expression vector of Claim 2 and a pharmaceutically acceptable carrier.